- Home
- HRTX vs PLX Comparison
HRTX vs PLX Comparison
Compare HRTX & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- PLX
- Stock Information
- Founded
- HRTX 1983
- PLX 1993
- Country
- HRTX United States
- PLX United States
- Employees
- HRTX N/A
- PLX N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HRTX Health Care
- PLX Health Care
- Exchange
- HRTX Nasdaq
- PLX Nasdaq
- Market Cap
- HRTX 203.5M
- PLX 204.9M
- IPO Year
- HRTX 1987
- PLX 1998
- Fundamental
- Price
- HRTX $1.11
- PLX $1.91
- Analyst Decision
- HRTX Strong Buy
- PLX Strong Buy
- Analyst Count
- HRTX 2
- PLX 1
- Target Price
- HRTX $4.50
- PLX $15.00
- AVG Volume (30 Days)
- HRTX 2.1M
- PLX 621.6K
- Earning Date
- HRTX 11-04-2025
- PLX 11-13-2025
- Dividend Yield
- HRTX N/A
- PLX N/A
- EPS Growth
- HRTX N/A
- PLX N/A
- EPS
- HRTX N/A
- PLX 0.07
- Revenue
- HRTX $155,097,000.00
- PLX $61,840,000.00
- Revenue This Year
- HRTX $10.62
- PLX $14.53
- Revenue Next Year
- HRTX $12.99
- PLX $75.77
- P/E Ratio
- HRTX N/A
- PLX $27.51
- Revenue Growth
- HRTX 12.60
- PLX 35.41
- 52 Week Low
- HRTX $1.04
- PLX $1.32
- 52 Week High
- HRTX $2.68
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- HRTX 39.29
- PLX 37.27
- Support Level
- HRTX $1.09
- PLX $1.70
- Resistance Level
- HRTX $1.14
- PLX $2.22
- Average True Range (ATR)
- HRTX 0.07
- PLX 0.14
- MACD
- HRTX 0.00
- PLX -0.06
- Stochastic Oscillator
- HRTX 27.08
- PLX 28.87
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.